Medtronic Shares First Results from New Symplicity Spyral RDN Study
Medtronic announced the first results from the high cardiovascular risk cohort of its SPYRAL AFFIRM study, showcasing significant and sustained blood pressure reductions with its Symplicity Spyral renal denervation system.
The study, which completed enrollment, reported data from 210 patients at 59 sites across Europe, Australia, and the U.S., demonstrating safe reductions with no increase in anti-hypertensive medication use at six months.
The findings were presented at the 2025 Transcatheter Cardiovascular Therapeutics conference in San Francisco, adding to the three-year Symplicity Spyral outcomes shared previously.
Investigators saw significant, safe and sustained blood pressure reductions with the RDN system.
The results highlight the potential of the Symplicity Spyral RDN system in treating patients with high cardiovascular risk.
Author's summary: Medtronic shares promising results from Symplicity Spyral RDN study.